Masami Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masami Yamamoto has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Tetsuya Tsukamoto
Oncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan
19 shared publications - Sachiyo Nomura
Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
18 shared publications - Bei Miao
Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, China
14 shared publications - Feiyue Zhang
Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
14 shared publications - Jiajia Wang
Oncology Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 shared publications - Juan Wang
Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
14 shared publications
Latest Publications
- 26 October 2026
- Published by Elsevier in Journal of Comparative Pathology
- Vol. 230, 62-66
Invasive candidiasis caused by Candida tropicalis in an endangered Ryukyu long-furred rat (Diplothrix legata)
- 26 October 2026
- Published by Elsevier in Journal of Comparative Pathology
- Vol. 230, 62-66
Invasive candidiasis caused by Candida tropicalis in an endangered Ryukyu long-furred rat (Diplothrix legata)
- Open Access
- 9 September 2026
- Published by Elsevier in Redox Biology
- Vol. 97
Cancer-associated fibroblast-derived POSTN as a metabolic “switch” shapes lipid-stressed macrophage polarization in gastric cancer
- 9 September 2026
- Published by Elsevier in Redox Biology
- Vol. 97
Open AccessCancer-associated fibroblast-derived POSTN as a metabolic “switch” shapes lipid-stressed macrophage polarization in gastric cancer
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9424
Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells
The cellular mechanisms underlying HER2-positive gastric cancer (HER2+ GC) responses to immunochemotherapy remain underexplored. Here, we perform longitudinal single-cell RNA-sequencing with paired TCR/BCR profiling on HER2+ and HER2-negative gastric cancer (HER2− GC) pre- and post-treatment to find dynamic immune remodeling during. Pre-treatment HER2+ GC displays an immunogenic microenvironment enriched with tumor-reactive T and B cells compared to HER2− GC. Following immunochemotherapy (anti-PD-1, XELOX/FOLFOX and anti-HER2), HER2+ GC display clonal expansions of tumor-reactive T cells, increased memory B cell differentiation, enhanced naïve B cell recruitment, and enriched B-T cell interaction. Mechanistically, vitamin B5 promotes human T cell proliferation in coculture with naïve B cells. Notably, B5 biosynthesis is enriched in tumor-infiltrating naïve B cells in GC patient samples, and serum B5 concentration is elevated in the HER2+PD-L1+ subset. In vivo, vitamin B5 supplementation boosts anti-PD-1 responses in female mice bearing subcutaneous cancers. Our data thus demonstrate a critical function for naïve B cells in immunochemotherapy response in HER2+ GC, and also implicate vitamin B5 supplementation for potentiating immune checkpoint blockade.
- 5 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9424
Open AccessVitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells
The cellular mechanisms underlying HER2-positive gastric cancer (HER2+ GC) responses to immunochemotherapy remain underexplored. Here, we perform longitudinal single-cell RNA-sequencing with paired TCR/BCR profiling on HER2+ and HER2-negative gastric cancer (HER2− GC) pre- and post-treatment to find dynamic immune remodeling during. Pre-treatment HER2+ GC displays an immunogenic microenvironment enriched with tumor-reactive T and B cells compared to HER2− GC. Following immunochemotherapy (anti-PD-1, XELOX/FOLFOX and anti-HER2), HER2+ GC display clonal expansions of tumor-reactive T cells, increased memory B cell differentiation, enhanced naïve B cell recruitment, and enriched B-T cell interaction. Mechanistically, vitamin B5 promotes human T cell proliferation in coculture with naïve B cells. Notably, B5 biosynthesis is enriched in tumor-infiltrating naïve B cells in GC patient samples, and serum B5 concentration is elevated in the HER2+PD-L1+ subset. In vivo, vitamin B5 supplementation boosts anti-PD-1 responses in female mice bearing subcutaneous cancers. Our data thus demonstrate a critical function for naïve B cells in immunochemotherapy response in HER2+ GC, and also implicate vitamin B5 supplementation for potentiating immune checkpoint blockade.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 2. BFAR drives gastrointestinal tumorigenesis
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 2. BFAR drives gastrointestinal tumorigenesis
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 6. BFAR is not ubiquitinated by PRP19
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 6. BFAR is not ubiquitinated by PRP19
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 3. Infiltration of macrophages and T cells is independent of BFAR
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 3. Infiltration of macrophages and T cells is independent of BFAR
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 4. Bfar knockdown restrains the neutrophil chemokines expressions
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 4. Bfar knockdown restrains the neutrophil chemokines expressions
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Primers used for real-time quantitative PCR
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Primers used for real-time quantitative PCR
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
The immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in gastric cancer. In this study, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9–BFAR–PRP19–YBX1 signaling axis. Multiomics analyses revealed that BFAR is overexpressed in gastric cancer and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T-cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feed-forward loop that sustains an immunosuppressive tumor microenvironment. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T-cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti–PD-1 therapy, whereas its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in gastric cancer.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
The immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in gastric cancer. In this study, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9–BFAR–PRP19–YBX1 signaling axis. Multiomics analyses revealed that BFAR is overexpressed in gastric cancer and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T-cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feed-forward loop that sustains an immunosuppressive tumor microenvironment. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T-cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti–PD-1 therapy, whereas its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in gastric cancer.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 8. BFAR is a inhibitory factor to anti-PD1 therapy
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 8. BFAR is a inhibitory factor to anti-PD1 therapy